Skip to content
2seventy bio logo — It’s about time we think smarter and faster than cancer.

2seventy bio

It’s about time we think smarter and faster than cancer.

Founded 2021 United States Cambridge, United States 122 employees Acquired Total: $614.62M Biotechnology, Health Care +1

General Information

Company Name 2seventy bio
Founded Year 2021
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 122
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Acquired
Business Model B2B2C, B2B
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with 2seventy bio. To contact 2seventy bio, visit 2seventybio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does 2seventy bio compare?

A PDF of 2seventy bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting 2seventy bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About 2seventy bio

2seventy bio is a progressive player in the field of immuno-oncology cell therapy, founded in 2021. With its headquarters in the United States, the company is dedicated to altering the future of cancer treatment. Their innovative approach is encapsulated in the slogan, "It’s about time we think smarter and faster than cancer."

The company's focus lies in the convergence of cancer cell metabolism, genomics, and immune responses, crafting therapies that essentially "think" as they outperform cancer's progression. By integrating deep biological insights with cutting-edge technology, 2seventy bio is striving to redefine the cancer therapy landscape.

In pursuit of its mission, 2seventy bio recently secured a substantial investment of $286.00M through an acquisition by Bristol-Meyers Squibb on 01 March 2025. This indicates a strong interest from major industry players in the biotechnology sphere, positioning the company for impactful growth and innovation in health care.

Business keywords: immuno-oncology, cell therapy, cancer treatment, cancer cell metabolism, genomics, immune response, tumor cell targeting, cellular therapies, cancer cell biology, genetics, therapeutic pipeline, disruptive therapies, oncology research, innovative cancer therapies

Services & Products

Research & Development
Clinical Trials
Product Development
Scientific Resources Provision
Medicines Access and Support

Target Customers

Patients with Cancer Patients with Hematological Diseases Neurological and Psychiatric Patients Healthcare Providers Patient Advocacy Groups Medical Researchers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $286.00M 1
Bristol-Meyers Squibb
01 Mar 2025
Post-IPO Equity $125.00M -
01 Feb 2023
Private Placement VC $170.00M 11
Casdin Capital, Boxer Capital +9
01 Mar 2022
IPO $33.62M -
01 Nov 2021

2seventy bio Alternatives & Competitors

View All Alternatives
2seventy bio vs
Kite Pharma
Kite Pharma United States

At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.

Acquired
4013 employees
Biotechnology, Health Care
2seventy bio vs

MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 for solid c...

5 employees
Biotechnology, Health Care
2seventy bio vs

Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.

Post-IPO Equity
14 employees
Biopharma, Biotechnology

FAQ About 2seventy bio

It’s about time we think smarter and faster than cancer.
2seventy bio was founded in 2021.
2seventy bio is headquartered in Cambridge, United States.
2seventy bio operates in Biotechnology, Health Care and Health and Wellness. Its work centres on immuno-oncology, cell therapy, cancer treatment and cancer cell metabolism. Its customers include Patients with Cancer, Patients with Hematological Diseases and Neurological and Psychiatric Patients.
2seventy bio has a B2B2C and B2B business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
2seventy bio has approximately 122 employees.
2seventy bio has completed 4 funding rounds, raising a total of $614.62M. The latest funding stage is Acquired.
2seventy bio offers: Research & Development, Clinical Trials, Product Development, Scientific Resources Provision, Medicines Access and Support.
Top alternatives and competitors to 2seventy bio include Kite Pharma, MetiMedi Co., Ltd., Trillium Therapeutics Inc., Faeth Therapeutics, Tango Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
2seventy bio and Kite Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for 2seventy bio, https://bouncewatch.com/company/2seventy-bio, updated 3 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout